Latest News
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
5 November 2026 - French biotech company Transgene (Euronext Paris:TNG) and the University of Copenhagen have dosed the first patient in the Phase 1 OV-PRIME-R trial evaluating BT-001 in patients with localised rectal cancer, Transgene announced on T...
Elicera Therapeutics secures Chinese patent allowance for ELC-401
5 November 2026 - Swedish clinical stage immuno-oncology company Elicera Therapeutics AB (STO: ELIC) on Thursday said the China National Intellectual Property Administration has issued a notice of allowance for a patent application covering its CAR T...
SK Biopharmaceuticals submits cenobamate supplemental New Drug Application to US FDA
5 November 2026 - SK Biopharmaceuticals Co Ltd, a South Korea-based pharmaceutical company, announced on Wednesday that it has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking approval of cenob...
Circular Genomics and PharmatrophiX collaborate on advancing circRNA biomarkers in neurodegenerative drug development
5 November 2026 - Circular Genomics Inc, a precision neurology company developing circular RNA (circRNA)-based biomarkers, and PharmatrophiX Inc, a clinical-stage biopharmaceutical company developing disease-modifying therapies for neurodegenerative ...
Viatris to pay quarterly dividend of USD0.12 per share
5 November 2026 - Global healthcare company Viatris Inc (Nasdaq:VTRS) announced on Wednesday that on its board of directors has declared a quarterly dividend of USD0.12 per share for each issued and outstanding share of the company's common stoc...